Sidney M. Bell, PhD (@sidneymbell)
Chan Zuckerberg Initiative
Mini workshop: California Departments of Public Health
June 10, 2021
Grubaugh, Nature Micro, 2019
SARS-CoV-2
(~7 day serial interval, ~25 subs/year)
ACTG
ACTT
AGTT
Antigenic variation
Genetic
variation
Measles
Antigenically uniform
Flu
Antigenically
diverse
Lifelong protection
Temporary cross-protection
Clades don't stick around very long because they're constantly being outcompeted by new clades
Flu
Dengue
Population susceptibility:
Previously circulating:
Population
immunity:
Clade growth:
**In flu, this is driven by natural infection, not vaccination
Wren, Bell et al., 2018
Neutralization?
+
+
Replication
How much serum (neutralizing antibodies) is necessary to block replication?
+
Replication
Virus A
Antibodies from patient recovered from virus A
+
Replication
Virus B, which showed up ~1 year later
Antibodies from patient recovered from virus A
+
Replication
O.G. SARS-CoV-2
Antibodies from patient recovered from O.G.
SARS-CoV-2
+
Replication
B.1.351
Antibodies from patient recovered from O.G. SARS-CoV-2
Antigenic similarity = how much sera is required to neutralize viral replication?
Serum
Test viruses
1x
2x
4x
(relative to autologous)
X
X
X
X
X
X
--
Log2
0
1
2
Titer
Flu, per year
3
O.G. vs B1.351 SARS-CoV-2
Starr et al, Cell Reports, 2021
Values from Juraska et al, PNAS 2018
John Huddleston
Antigenic change
Surface protein mutations
Recent clade expansion
Impact on protein function
+
+
+
Growth rate @
next year
Titers
Sequence
Trees
Sequence + modeling
John Huddleston
John Huddleston
John Huddleston
Many thanks to the Bedford lab
& the Nextstrain team
Antigenic cartography
Visualize antigenic space via a low-dimensional embedding
Evolution-based models
Assign antigenic change to branches or substitions, interpolate across dataset
Population dynamics
Antigenic fitness & clade turnover